Astrazeneca Ab

Adam Herring

David Cladingboel

Annika Björe

Gert Strandlund

Johan Kajanus

Karin Lövqvist

Christina Olsson

Lal Cheema

Carl-Gustav Sigfridsson

Neil Barnwell

Gareth Ensor

Robert Lundqvist

There is provided compounds of formula I, wherein R, R, R, Rto R, X, Y and Z have meanings given in the description, which compounds are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Oxabispidine compounds for the treatment of cardiac arrhythmias

There is provided substantially crystalline forms of 4-({3-[7-(3,3-dimethyl-2-oxobutyl) -9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]propyl}amino)benzo-nitrile; tert-butyl 2 -{7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate; tert-butyl 2-{7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate; or tert-butyl 2-{7-[2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of cardiac arhythmias.

3,7-Diazabicyclo [3.3.1] formulations as anti-arrhythmic compounds

Growing community of inventors

Loughborough, United Kingdom

Adam Herring